Unknown

Dataset Information

0

Ongoing developments in RSV prophylaxis: a clinician's analysis.


ABSTRACT: Respiratory syncytial virus (RSV) is the most common respiratory pathogen in infants and young children worldwide. Lower respiratory tract infection due to RSV is one of the most common causes of hospitalization for infants, especially those born premature or with chronic lung or heart disease. Furthermore, RSV infection is an important cause of morbidity in adults, particularly in the elderly and immunocompromised individuals. The acute phase of this infection is often followed by episodes of wheezing that recur for months or years and usually lead to a physician diagnosis of asthma. RSV was discovered more than 50 years ago, and despite extensive research to identify pharmacological therapies, the most effective management of this infection remains supportive care. The trial of a formalin-inactivated RSV vaccine in the 1960s resulted in priming the severe illness upon natural infection. Currently, Palivizumab is the only available option for RSV prophylaxis, and because of restricted clinical benefits and high costs, it has been limited to a group of high-risk infants. There are several ongoing trials in preclinical, Phase-I, Phase-II, or Phase-III clinical stages for RSV vaccine development based on various strategies. Here we review the existing available prophylactic options, the current stages of RSV vaccine clinical trials, different strategies, and major hurdles in the development of an effective RSV vaccine.

PROVIDER: S-EPMC5541395 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC5698904 | BioStudies
| S-EPMC3835183 | BioStudies
2018-01-01 | S-EPMC6466083 | BioStudies
| S-EPMC5792496 | BioStudies
| S-EPMC4409022 | BioStudies
| S-EPMC3893236 | BioStudies
| S-EPMC5244814 | BioStudies
| S-EPMC7116660 | BioStudies
| S-EPMC7029767 | BioStudies
| S-EPMC6498742 | BioStudies